Skip to main content

Chapters

Transcript

Video

Focused Cancer Updates: Neoadjuvant Therapy for Breast Cancer and Managing Immunotherapy Toxicity

An expert panel delivers news to inform therapy and monitoring decisions, including a look at how the I-SPY 2 trial is accelerating evaluation of promising agents in high-risk breast cancer (as well as cutting down on unlikely-to-help treatments); opportunities to reduce late recurrence in patients with HR-positive tumors; better ways to address immunotherapy's toxic effects in survivors, part of the mission of UCSF's new CITE (Cancer Immunotherapy Toxicity Evaluation) Program; and immediate steps to take when cancer survivors present with fatigue, thirst or other hormonal symptoms.

Published

May 5, 2023

Created by

UCSF MedConnection

Related Presenters

Laura Esserman, MD, MBA

Laura Esserman, MD, MBA

Director, Carol Franc Buck Breast Care Center

View Full Profile

Jo Chein, MD

Breast oncologist Medical
Director, Breast Medical Oncology

View Full Profile

Katy K. Tsai, MD

Katy K. Tsai, MD

Oncologist and melanoma specialist

View Full Profile

Zoe Quandt, MD

Endocrinologist

View Full Profile

Related Videos

High Risk for Breast Cancer: Methods and Schedules to Ensure Optimal Screening

High Risk for Breast Cancer: Methods and Schedules to Ensure Optimal Screening

Hematologist-oncologist Elham Vosoughi, MD, starts with an update on breast cancer stats, noting that incidence in the United States is increasing by 1% every year – with an even sharper rise for women under 50.

Making Sense of MGUS: How to Detect Plasma Cell Disorders and Assess Associated Risks

Making Sense of MGUS: How to Detect Plasma Cell Disorders and Assess Associated Risks

Affecting up to 5% of the U.S. population (and increasingly common with age), monoclonal gammopathy of undetermined significance (MGUS) raises the risk of multiple myeloma, but – as its full name suggests – it can be hard to say by how much.

Advances (and Uncertainties) in Oncology: Current and Future Roles of Antibody Drug Conjugates

Advances (and Uncertainties) in Oncology: Current and Future Roles of Antibody Drug Conjugates

Focusing on common bladder, lung and breast cancers, three UCSF oncologists describe how antibody drug conjugates (ADCs) are changing the treatment landscape, especially for refractory cases

New Keys to Cancer Care: How 2023 Findings Impact Treatment Decisions

New Keys to Cancer Care: How 2023 Findings Impact Treatment Decisions

These four collaborative talks from UCSF and John Muir Health specialists shine a light on recent study results that should inform treatment planning for patients with a variety of GI, breast, lung and blood cancers.

Integrative Approaches to Symptom Management for Cancer Patients

Integrative Approaches to Symptom Management for Cancer Patients

This presentation from a variety of UCSF specialists covers a range of practical topics, from how clinicians can easily meet the new DEA educational requirement for opioid use disorder to the current evidence on mindfulness meditation's ...

Advances in Breast Cancer Care: Individualized Screening, Treatments and Follow-Up

Advances in Breast Cancer Care: Individualized Screening, Treatments and Follow-Up

Karen Goodwin, DO, covers everything from how to answer patients’ questions on mammogram frequency to how to counsel them on breast cancer prevention.

CAR T-Cells for Hematologic Malignancies and Beyond

CAR T-Cells for Hematologic Malignancies and Beyond

In this data-drenched discussion, UCSF specialists review how CAR T-cells are being used in hematologic malignancies, including aggressive lymphoma and difficult-to-treat myeloma, as well as for solid tumors, and reveal what's on the horizon ...

Better Cancer Care: Pearls From the Best Studies of 2022

Better Cancer Care: Pearls From the Best Studies of 2022

Focusing on blood, breast and lung cancers, our specialists deliver exciting findings from the latest phase III trials.

Cutting-Edge Approaches to Prostate and Breast Cancers: Reach the Right Decision for Each Patient

Cutting-Edge Approaches to Prostate and Breast Cancers: Reach the Right Decision for Each Patient

In this grand rounds presentation, you’ll learn the best risk assessment tools for prostate cancer patients, the latest surgical techniques, such as fluorescence imaging and high-intensity focused ultrasound, and tests that allow for matching ...

Additional Links

U.S. News Honor Roll Best Hospitals 24-25

This Video Content is available for informational and educational purposes only. UCSF does not make any representation or warranties with respect to the accuracy, applicability, fitness, or completeness of the Video Content. The Regents of the University of California and its officers, agents or employees (UCSF) will not be liable for any damages of any kind arising from any use of the Video Content, which is provided as is, and without warranties. The Video Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read or seen on the Site.

©2002 - 2025 The Regents of The University of California